Home > Cardiology > Reduction in atrial arrhythmias in patients with CIED on SGLT2 inhibitors

Reduction in atrial arrhythmias in patients with CIED on SGLT2 inhibitors

Expert
Prof. Ilan Goldenberg, University of Rochester, NY, USA
Conference
AHA 2021
Trial
DAPA-HF
SGLT2 inhibitors were associated with a significant reduction in atrial arrhythmias (AA) and all-cause mortality in patients with cardiac implantable electronic devices (CIED). The results of this real-world study indicate that SGLT2 inhibitors may have antiarrhythmic effects, that add to the beneficial effects that these agents exert on patients with heart failure (HF). The study was presented during the virtual meeting of the American Heart Association Scientific Sessions, held from 13 to 15 November, 2021. Medicom interviewed Prof. Ilan Goldenberg (University of Rochester, NY, USA), first author of the study, to discuss the implications of these findings [1]. “Sodium gluco...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on